Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal indomethacin plus mesna versus rectal indomethacin for prevention of post-ERCP pancreatitis
IRCT20121021011192N16Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of indomethacin and mesna in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Pancreatitis occurrence. Started Sep 2023; status: completed.
02
Drugs
indomethacinmesna
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on IRCT20121021011192N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20121021011192N16.